HELEN HESLOP to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
This is a "connection" page, showing publications HELEN HESLOP has written about Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Connection Strength
0.527
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
Score: 0.149
-
Outcomes of transplantation with matched-sibling and unrelated-donor bone marrow in children with leukaemia. Lancet. 1997 Sep 13; 350(9080):767-71.
Score: 0.126
-
Fall of the mutants: T cells targeting BCR-ABL. Blood. 2017 02 02; 129(5):539-540.
Score: 0.121
-
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood. 2008 Sep 01; 112(5):1876-85.
Score: 0.066
-
Selective depletion of donor alloreactive T cells without loss of antiviral or antileukemic responses. Blood. 2003 Sep 15; 102(6):2292-9.
Score: 0.047
-
Tumor necrosis factor mediates autocrine growth inhibition in a chronic leukemia. J Immunol. 1989 Dec 01; 143(11):3828-34.
Score: 0.018